Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Neurocrine Biosciences, Inc. (NASDAQ:NBIX) have returned -7% and 12% over the past six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for the State Street SPDR S&P 500 ETF Trust.
Axsome and Neurocrine are building their businesses around treatments for neurological and psychiatric conditions. Both have several opportunities to expand beyond their existing products, but they are at different stages of commercial development. Axsome is growing faster, while Neurocrine has a larger business, positive earnings, and a more established commercial operation.
AXSM ranked 1st in our list of the 10 Best Under-the-Radar Stocks to Invest In. To see which stocks outranked it, click HERE.
Axsome’s revenue grew 46% year over year to $218.4 million in Q2 2026, driven largely by AUVELITY, its depression treatment. Sales of AUVELITY increased 51% to $180.3 million. The bigger opportunity may be its recent launch for agitation associated with Alzheimer’s disease, which opens up another market for an existing drug. During the first eight weeks of the launch, new-to-brand prescriptions among patients aged 65 and older increased 126% compared with the preceding quarter’s corresponding period. It’s an encouraging start, although eight weeks is too short to judge the launch’s long-term potential.
Axsome also has SUNOSI for excessive daytime sleepiness and SYMBRAVO for migraine, along with a pipeline targeting conditions such as narcolepsy, ADHD, and fibromyalgia. The opportunity is to build several meaningful products rather than depend on AUVELITY alone. The challenge is that Axsome is still spending heavily to commercialize its drugs. It reported a $51.3 million net loss in Q2, and its $320 million cash balance needs to support both commercial expansion and pipeline development.
On January 31, we wrote an article about 10 Mid-cap Stocks To Buy. The number 1 stock on that list has returned almost 30% since. AXSM ranked 6th on that list.
Neurocrine Has Already Built a Profitable Business
Neurocrine’s commercial business is considerably larger. Revenue increased 39% to $959 million in Q2, including a partial-quarter contribution from VYKAT XR, which it acquired through the $2.9 billion purchase of Soleno Therapeutics. INGREZZA, its treatment for tardive dyskinesia, generated $716 million in sales, up 15%. CRENESSITY, used to treat congenital adrenal hyperplasia, brought in $184 million, while VYKAT XR adds another opportunity in Prader-Willi syndrome.
The important difference is that Neurocrine isn’t relying on a single upcoming launch to drive its growth. INGREZZA continues to generate substantial revenue, CRENESSITY has reached only about 15% of its estimated diagnosed patient population, and Neurocrine expects VYKAT XR to return to sequential growth as it integrates the business.
There is still execution risk. INGREZZA accounts for most of Neurocrine’s revenue, and the company will eventually have to contend with Medicare pricing changes. Its pipeline also needs to deliver. Phase 3 results for osavampator in major depressive disorder and direclidine in schizophrenia are expected in 2027. Positive results could open up additional markets, but those opportunities aren’t guaranteed.
NBIX ranked 5th in our list of the 10 High Growth Stocks to Buy Right Now. To see which stocks outranked it, click HERE.
Valuation Analysis: Neurocrine Is Cheaper, but Axsome Has More Growth Potential
Axsome Therapeutics, Inc. trades at 32.15x forward earnings, while its trailing P/E is not meaningful because it is still losing money. Neurocrine, on the other hand, trades at 20.73x trailing earnings and 14.12x forward earnings. That makes Neurocrine the cheaper stock by a fair margin. The question is whether Axsome’s faster growth is enough to make up for the difference.
There is a reasonable argument for paying more for Axsome. Its revenue is growing faster, AUVELITY is expanding into a new indication, and the company has several potential product launches ahead. If Alzheimer’s-related agitation becomes a meaningful market for AUVELITY, Axsome could eventually grow into its valuation. But investors are paying for a business that still needs to demonstrate that its commercial expansion can translate into sustained profitability. The launch is promising, not yet proven, and higher selling expenses could delay the improvement investors are expecting.
Neurocrine Biosciences, Inc. has less to prove on that front. It generated $2.85 in non-GAAP earnings per share in Q2 and has three commercial products contributing to revenue. Its lower forward P/E suggests the market isn’t demanding the same growth premium it assigns to Axsome. The acquisition of Soleno adds another growth driver, although Neurocrine spent approximately $2.9 billion on the deal and ended Q2 with about $482 million in cash and marketable securities. Investors also need to account for acquisition-related amortization when comparing GAAP and adjusted earnings.
DON’T MISS: Top 10 Large-Cap Stocks to Buy At 52-Week Lows
Conclusion
Neurocrine seems like the better choice at current prices. Axsome has a lot going for it, and AUVELITY could be a much bigger business as it expands into new markets. But the company still has to prove it can turn that growth into profits. Neurocrine is already doing that, and investors aren’t paying nearly as much for its future earnings. That makes NBIX the better buy right now.
Market Sentiment
Axsome Therapeutics was held by 74 hedge funds with a combined stake value of about $2.00 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 55 hedge fund holders with a cumulative investment value of around $1.14 billion in the previous quarter.
Neurocrine Biosciences, on the other hand, was held by 45 hedge funds with a combined stake value of about $2.46 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 53 hedge fund holders with a cumulative investment value of around $2.61 billion in the previous quarter.
READ NEXT: AbbVie (ABBV) Outgrew Humira’s Collapse. Is its Forward P/E Fair for What Comes Next? and Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
This article is originally published at Insider Monkey.
Hedge Fund Resource Center